Clinical trials: Head or Neck Cancer
Subjects With p16 Positive/HPV Positive Squamous Cell Carcinomas of the Oropharynx
HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer
To assess in an exploratory manner, the pronostic utility for locoregional control, progression-free and distant metastasis-free survival of a pre-therapy and post-therapy blood DNA test of HPV E6 and E7 DNA for subtypes 16 and…
- Trial name
- NCT01984359
- Testing
- Obtaining Human tissue
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Head and Neck Cancer
Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System
The goal of this clinical research study is to learn if using the PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of the body that has, or is suspected to have cancer will give researchers the same or…
- Trial name
- NCT01030497
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult, Colorectal Cancer
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma
- Trial name
- NCT06270082
- Testing
- IK-595
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- Ikena Oncology
Solid Tumor, Non Small Cell Lung Cancer
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05653882
- Testing
- etakafusp alfa (AB248), pembrolizumab
- Where
- 20 sites in United States
- Volunteers
- 552 people
- Sponsor
- Asher Biotherapeutics, Inc.
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell…
- Trial name
- NCT06525220
- Testing
- Petosemtamab, Pembrolizumab
- Where
- 202 sites in United States, Argentina and 26 more
- Volunteers
- 699 people
- Sponsor
- Genmab
Squamous Cell Carcinoma of Head and Neck
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
Subjects will receive treatment with nivolumab monotherapy at 240mg flat dose as a 30 minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death…
- Trial name
- NIVACTOR (NCT05802290)
- Testing
- Nivolumab 240 MG in 24 ML Injection
- Where
- 23 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Advanced Solid Tumors
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes and/or to distant parts of the body and that are…
- Trial name
- NCT05537740
- Testing
- BAY3375968, Pembrolizumab
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 129 people
- Sponsor
- Bayer
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC
The aim of the trial is to evaluate the clinical benefit (efficacy, safety, preservation of autonomy) of cetuximab-carboplatin-5FU combination as first line treatment of recurrent or metastatic head and neck squamous cell…
- Trial name
- ELANFIT (NCT01864772)
- Testing
- Carbo, 5FU, Cetuximab
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
This phase II trial is studying erlotinib hydrochloride to see how well it works in treating patients with advanced esophageal cancer or stomach cancer.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT00045526
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell…
- Trial name
- NCT07059221
- Testing
- SHR-A2102, Adebrelimab, Cetuximab
- Where
- 2 sites in China
- Volunteers
- 210 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Esophagus Cancer
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if Afatinib plus Palbociclib works in previously treated recurrent or metastatic esophageal squamous cell carcinoma.
- Trial name
- NCT06753747
- Testing
- Palbociclib, Afatinib(30mg), Afatinib(40mg)
- Where
- China
- Volunteers
- 45 people
- Sponsor
- West China Hospital
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
The goal of this research study is to learn which therapy order (adding pembrolizumab during vs. after cisplatin and radiation) may be more effective in treating head and neck cancer, as well as learn the side effects of these…
- Trial name
- NCT02777385
- Testing
- Pembrolizumab, Cisplatin, IMRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Dan Zandberg
Radioiodine Refractory Differentiated Thyroid Cancer
Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer
177Lu-LNC1004 Injection, a radiopharmaceutical targeting FAP, has demonstrated preliminary antitumor effect in advanced FAP-positive solid tumor patients.
- Trial name
- NCT06898437
- Testing
- 177Lu-LNC1004 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Cancer-related Fatigue
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
Eighty to 90% of SCCHN (squamous cell carcinoma of head and neck) patients in Taiwan were betel quid chewers. Thirty to 40% of them experienced mucositis World Health Organization (WHO) grade 3 from cisplatin/flurouracil (FU) in…
- Trial name
- NCT01720563
- Testing
- Astragalus polysaccharides 500 mg, Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks
- Where
- Taiwan
- Volunteers
- 17 people
- Sponsor
- PhytoHealth Corporation
Carcinoma, Squamous Cell of Head and Neck
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the most common cancer arising in the upper aerodigestive tract, and is the sixth leading incident cancer worldwide.
- Trial name
- NCT02277184
- Testing
- Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Julie E. Bauman, MD, MPH
Esophageal Cancer
The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational Study
To clarify the effect of Two-field or Three-field Lymphadenectomy on the survival of esophageal squamous cell carcinoma.
- Trial name
- NCT05617352
- Testing
- Since the data were collected retrospectively, there were no interventions
- Where
- China
- Volunteers
- 1,659 people
- Sponsor
- Yongtao Han
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.